AbbVie reports strong revenue growth amid market volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy ABBV?
Source: Fool
AbbVie Inc's stock fell 3.02% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 0.12% and the S&P 500 down 0.24%.
The company's revenue from its new drugs Skyrizi and Rinvoq surged to $5 billion and $2.37 billion in Q4 2025, reflecting year-over-year increases of 32% and 29.5%, respectively. This strong performance supports AbbVie's transition following the loss of Humira's exclusivity, enhancing its long-term profitability and stability as a Dividend King.
Despite the stock's decline, AbbVie's strong revenue growth indicates resilience in its business model, attracting investors seeking stability during market volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 211.120
Low
223.00
Averages
252.00
High
289.00
Current: 211.120
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Advances Dermatology Research at AAD 2026
- Research Presentation: AbbVie will present 24 research abstracts at the 2026 American Academy of Dermatology Annual Meeting, including a significant late-breaking study that underscores the company's leadership in advancing treatment standards for immune-mediated skin diseases, which is expected to reshape future treatment paradigms.
- Long-Term Efficacy Data: The KEEPsAKE 1 Phase 3 trial shows that risankizumab maintains radiographic non-progression in patients with active psoriatic arthritis over five years, indicating its potential to significantly improve patient quality of life.
- Safety Studies: Long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis from three Phase 3 studies reveal six years of results, further solidifying its application prospects and potentially enhancing market acceptance.
- Real-World Evidence: The AD-VISE study provides real-world effectiveness data for upadacitinib across different body regions, highlighting its importance in patient-reported outcomes, which may influence prescribing decisions and treatment choices among physicians.
See More
Eli Lilly Faces Competitive Pressure but Maintains Optimistic Outlook
- Market Performance: Despite leading the weight-loss medicine market, Eli Lilly's shares have fallen 15% this year, raising concerns about intensified competition in its core niche that could erode pricing power and profits.
- Margin Improvement: Since 2020, Eli Lilly's gross and operating margins have significantly improved, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced manufacturing efficiency.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion since 2020 to expand its manufacturing capacity, which may hurt profits and margins in the short term but is expected to lower costs and boost capacity, driving significant economies of scale in the long run.
- Artificial Intelligence Initiatives: Eli Lilly has built the largest supercomputer in the pharmaceutical industry with Nvidia's help, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially having a positive impact across the business.
See More
Eli Lilly's Competitive Margin Analysis
- Margin Improvement: Since 2020, Eli Lilly has significantly improved its gross and operating margins, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced drug manufacturing efficiency.
- Competitive Market Pressure: Despite leading the weight-loss drug market, Eli Lilly's shares have fallen 15% this year, raising concerns about potential fierce competition that could erode pricing power and profits in the future.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion in expanding its manufacturing capacity since 2020, which may hurt profits in the short term but is expected to lower costs and enhance economies of scale in the long run.
- Artificial Intelligence Applications: Eli Lilly has partnered with Nvidia to build the largest supercomputer in the pharmaceutical industry, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially benefiting the entire business.
See More
AbbVie Increases Dividend by Over 330% Since 2013
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, which not only enhances investor income expectations but also boosts the company's market appeal, reflecting its stable cash flow and profitability.
- Strong Revenue Growth: Despite losing patent protection for Humira, AbbVie reported an 8.6% year-over-year revenue increase in 2025, indicating the resilience of its product portfolio and sustained market demand, further solidifying its position in the pharmaceutical industry.
- Robust R&D Pipeline: With over 90 drugs currently in development, AbbVie's extensive pipeline not only secures future revenue growth but also demonstrates the company's ongoing commitment to innovation and strategic planning in drug development.
- Reasonable Valuation Levels: AbbVie’s forward-looking P/E ratio stands at 14, slightly above the five-year average of 13, suggesting that the market's growth expectations are reasonable while providing investors with a relatively attractive entry point.
See More
AbbVie: A Reliable Source of Dividend Income
- Dividend Yield Advantage: AbbVie boasts a dividend yield of 3.38%, significantly higher than the S&P 500 average of 1.1%, making it an ideal choice for income-seeking investors looking to cover living expenses or reinvest.
- Dividend Payment Capability: With a recent dividend of $1.73 per share, translating to an annual payout of $6.92, investors aiming for $10,000 in annual dividends would need to purchase 1,445 shares, costing approximately $296,225, highlighting its reliable dividend payment.
- Consistent Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, and when combined with Abbott's history, it has achieved annual dividend growth for over 25 years, showcasing its appeal as a long-term investment.
- Strong Growth Potential: Despite losing patent protection for its blockbuster drug Humira, AbbVie’s 2025 revenue still grew by 8.6% year-over-year, and its pipeline of over 90 drugs in development indicates promising future growth, further enhancing its investment value.
See More
White House Hosts First Humanoid Robot Guest
- High-Profile Showcase: The White House hosted its first humanoid robot, Figure 3, during the Global Coalition Summit, showcasing advancements in U.S. humanoid robotics and highlighting the technology's significance in global tech competition, likely boosting brand recognition for Figure AI.
- Educational Potential: Melania Trump promoted the use of the robot for AI in children's education, suggesting that such robots could become interactive educators at home, which could significantly enhance the technological aspect of family education and its societal implications.
- Funding and Valuation: Figure AI raised over $1 billion in its Series C funding round in September, achieving a post-money valuation of $39 billion, with plans to deploy thousands of robots in homes and logistics, reflecting strong investor enthusiasm for physical AI.
- Legal Risk Awareness: The ongoing lawsuit against Figure AI may be reexamined due to Melania's endorsement, as a former safety head alleged safety concerns regarding the robots, emphasizing the need for safety standards in humanoid robotics development, which could impact the company's reputation and future growth.
See More
AbbVie Advances Dermatology Research at AAD 2026
- Research Presentation: AbbVie will present 24 research abstracts at the 2026 American Academy of Dermatology Annual Meeting, including a significant late-breaking study that underscores the company's leadership in advancing treatment standards for immune-mediated skin diseases, which is expected to reshape future treatment paradigms.
- Long-Term Efficacy Data: The KEEPsAKE 1 Phase 3 trial shows that risankizumab maintains radiographic non-progression in patients with active psoriatic arthritis over five years, indicating its potential to significantly improve patient quality of life.
- Safety Studies: Long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis from three Phase 3 studies reveal six years of results, further solidifying its application prospects and potentially enhancing market acceptance.
- Real-World Evidence: The AD-VISE study provides real-world effectiveness data for upadacitinib across different body regions, highlighting its importance in patient-reported outcomes, which may influence prescribing decisions and treatment choices among physicians.
See More
Eli Lilly Faces Competitive Pressure but Maintains Optimistic Outlook
- Market Performance: Despite leading the weight-loss medicine market, Eli Lilly's shares have fallen 15% this year, raising concerns about intensified competition in its core niche that could erode pricing power and profits.
- Margin Improvement: Since 2020, Eli Lilly's gross and operating margins have significantly improved, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced manufacturing efficiency.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion since 2020 to expand its manufacturing capacity, which may hurt profits and margins in the short term but is expected to lower costs and boost capacity, driving significant economies of scale in the long run.
- Artificial Intelligence Initiatives: Eli Lilly has built the largest supercomputer in the pharmaceutical industry with Nvidia's help, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially having a positive impact across the business.
See More
Eli Lilly's Competitive Margin Analysis
- Margin Improvement: Since 2020, Eli Lilly has significantly improved its gross and operating margins, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced drug manufacturing efficiency.
- Competitive Market Pressure: Despite leading the weight-loss drug market, Eli Lilly's shares have fallen 15% this year, raising concerns about potential fierce competition that could erode pricing power and profits in the future.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion in expanding its manufacturing capacity since 2020, which may hurt profits in the short term but is expected to lower costs and enhance economies of scale in the long run.
- Artificial Intelligence Applications: Eli Lilly has partnered with Nvidia to build the largest supercomputer in the pharmaceutical industry, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially benefiting the entire business.
See More
AbbVie Increases Dividend by Over 330% Since 2013
- Significant Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, which not only enhances investor income expectations but also boosts the company's market appeal, reflecting its stable cash flow and profitability.
- Strong Revenue Growth: Despite losing patent protection for Humira, AbbVie reported an 8.6% year-over-year revenue increase in 2025, indicating the resilience of its product portfolio and sustained market demand, further solidifying its position in the pharmaceutical industry.
- Robust R&D Pipeline: With over 90 drugs currently in development, AbbVie's extensive pipeline not only secures future revenue growth but also demonstrates the company's ongoing commitment to innovation and strategic planning in drug development.
- Reasonable Valuation Levels: AbbVie’s forward-looking P/E ratio stands at 14, slightly above the five-year average of 13, suggesting that the market's growth expectations are reasonable while providing investors with a relatively attractive entry point.
See More
AbbVie: A Reliable Source of Dividend Income
- Dividend Yield Advantage: AbbVie boasts a dividend yield of 3.38%, significantly higher than the S&P 500 average of 1.1%, making it an ideal choice for income-seeking investors looking to cover living expenses or reinvest.
- Dividend Payment Capability: With a recent dividend of $1.73 per share, translating to an annual payout of $6.92, investors aiming for $10,000 in annual dividends would need to purchase 1,445 shares, costing approximately $296,225, highlighting its reliable dividend payment.
- Consistent Dividend Growth: AbbVie has increased its dividend by over 330% since 2013, and when combined with Abbott's history, it has achieved annual dividend growth for over 25 years, showcasing its appeal as a long-term investment.
- Strong Growth Potential: Despite losing patent protection for its blockbuster drug Humira, AbbVie’s 2025 revenue still grew by 8.6% year-over-year, and its pipeline of over 90 drugs in development indicates promising future growth, further enhancing its investment value.
See More
White House Hosts First Humanoid Robot Guest
- High-Profile Showcase: The White House hosted its first humanoid robot, Figure 3, during the Global Coalition Summit, showcasing advancements in U.S. humanoid robotics and highlighting the technology's significance in global tech competition, likely boosting brand recognition for Figure AI.
- Educational Potential: Melania Trump promoted the use of the robot for AI in children's education, suggesting that such robots could become interactive educators at home, which could significantly enhance the technological aspect of family education and its societal implications.
- Funding and Valuation: Figure AI raised over $1 billion in its Series C funding round in September, achieving a post-money valuation of $39 billion, with plans to deploy thousands of robots in homes and logistics, reflecting strong investor enthusiasm for physical AI.
- Legal Risk Awareness: The ongoing lawsuit against Figure AI may be reexamined due to Melania's endorsement, as a former safety head alleged safety concerns regarding the robots, emphasizing the need for safety standards in humanoid robotics development, which could impact the company's reputation and future growth.
See More
